The Globe and Mail reports in its Friday, Nov. 22, edition that Raymond James analyst Michael Freeman has reaffirmed his "market perform" recommendation for HLS Therapeutics. The Globe's David Leeder writes in the Eye On Equities column that Mr. Freeman increased his share target to $5 from $4. Analysts on average target the shares at $5.65. Mr. Freeman says in a note: "Following 3Q24 earnings, we see HLS refining and improving its cost structure to suit what may be moderate (vs. hockey stick) growth of its Vascepa asset in the medium term, making particularly important strides through the termination of its co-promotion agreement with Pfizer. We see these cost reductions materially improving HLS's adjusted EBITDA profile, which we view positively. While the company does continue to see Vascepa grow steadily, we believe HLS's platform is now much better situated to balance growth and profitability, where it previously assumed aggressive growth, which has not (yet) been forthcoming. HLS's refreshed management team has done well to apply solid financial discipline to the organization such that the story has the potential to work on quasi-linear Rev. growth rather than relying on quasi-exponential."